HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX)

HC Wainwright restated their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

Immix Biopharma Stock Down 1.5 %

Shares of IMMX stock opened at $2.01 on Tuesday. Immix Biopharma has a fifty-two week low of $1.55 and a fifty-two week high of $7.75. The firm’s 50 day moving average price is $2.16 and its two-hundred day moving average price is $3.19. The stock has a market cap of $53.08 million, a price-to-earnings ratio of -2.16 and a beta of 0.17.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities analysts forecast that Immix Biopharma will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Several hedge funds have recently modified their holdings of the stock. OLD National Bancorp IN purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at approximately $69,000. Imprint Wealth LLC increased its stake in Immix Biopharma by 49.4% during the 4th quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after buying an additional 11,400 shares during the period. Tocqueville Asset Management L.P. lifted its holdings in Immix Biopharma by 89.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after buying an additional 17,800 shares in the last quarter. Jump Financial LLC purchased a new position in Immix Biopharma in the 4th quarter valued at about $128,000. Finally, Tritonpoint Wealth LLC acquired a new stake in shares of Immix Biopharma during the first quarter valued at about $75,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.